

## References

I-126

1. Glassia, Alpha-1 Proteinase Inhibitor (Human) prescribing information; Baxter Healthcare Corporation, Westlake Village, CA.
2. Prolastin/C prescribing information. Grifols Therapeutics, Inc., Research Triangle Park, NC. November 2013.
3. Aralast/NP prescribing information. Baxter Healthcare Corporation, Westlake Village, CA. March 2014.
4. Zemaira prescribing information. CSL Behring LLC, Kankakee, IL. May 2013.
5. Chotirmall S, Al-Alawi M, McEnery T, et al. Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes. *Ther Clin Risk Manag.* 2015;11:143–151.
6. Brode S, Ling S, Chapman K. Alpha-1 antitrypsin deficiency: A commonly overlooked cause of lung disease. *CMAJ.* 2012;184(12):1365–1371.
7. Izaguirre D, Lanza J, Klaus-Dieter L, et al. Alpha1-antitrypsin deficiency workup. *Medscape.*2014.
8. Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin deficiency. *Am J Respir Crit Care Med.* 2012;185:246-259.
9. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010.
10. Stoller JK, Bennett JW. Alpha-1 antitrypsin deficiency. National Organization for Rare Disorders (NORD); Last updated January 27, 2014.
11. The American Thoracic Society. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with Alpha-1 antitrypsin deficiency.
12. Alpha 1-proteinase inhibitor (Human) *Pharmacy and Therapeutics.* 2010;35(3)2-6.
13. Campos MA, Kueppers F, Stocks JM et al. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: A multicenter randomized, double-blind, crossover study (SPARK) Clinical Trial Identifier: NCT01213043; *COPD: Journal of Chronic Obstructive Pulmonary Disease.* 2013;10,6;687-695.
14. Nelson D, Teckman J, Bisceglie A, et al. Diagnosis and Management of Patients with a1-Antitrypsin (A1AT) Deficiency. *Clin Gastroenterol Hepatol.* 2012;10(6):575-580.
15. Stockley R, Miravittles M, Vogelmeier C. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalized approach. *Orphanet J Rare Dis.* 2013;8:149.
16. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. *Can Respir J.* 2012;19(2):109–116

17. Henao M, Craig T. Understanding alpha-1 antitrypsin deficiency: A review with an allergist's outlook. *Allergy And Asthma Proceedings*.2017;38(2):98-107.
18. Vogelmeier C, Criner G, Agustí A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *American Journal Of Respiratory And Critical Care Medicine*. 2017;195(5):557-582.
19. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. *Bulletin of the World Health Organization*.1997;75(5):397-415.
20. Sorrells S, Camprubi S, Griffin R, et al. SPARTA clinical trial design: Exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency. *Resp Med*. 2015;490-499.
21. Tirado-Conde G, Lara B, Miravittles M. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency. *Ther Adv Resp Diseas*. 2008;13-21.
22. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
23. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
24. MCG™ Care Guidelines, 21st edition, 2017, Home Infusion Therapy, CMT: CMT-0009(SR).
25. MICROMEDEX®SOLUTIONS Compendia. 2017. Alpha-1 Proteinase Inhibitor Human.
26. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Alpha-1-proteinase Inhibitor.